ADMA BIOLOGICS, INC. Cash and Restricted Cash
ADMA BIOLOGICS, INC. (ADMA) had Cash and Restricted Cash of $136.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $136.02M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138.15M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87.63M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.38M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $136.02M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $138.15M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $87.63M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $61.38M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $90.28M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $71.63M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $103.15M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $86.71M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $88.24M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $45.33M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $51.35M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $74.16M 10-Q · filed 2024-11-07 | $74.16M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $62.51M 10-Q · filed 2024-08-08 | $62.51M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $69.20M 10-Q · filed 2024-05-09 | $69.20M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $86.52M 10-K · filed 2026-02-25 | $86.52M 10-K · filed 2023-03-23 |
| 2022-09-30 | $34.91M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $52.42M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $69.50M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $51.09M 10-K · filed 2025-03-18 | $51.09M 10-K · filed 2022-03-24 |
| 2021-09-30 | $34.41M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $42.41M 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $61.97M 10-Q · filed 2022-05-11 | |
| 2020-12-31 | $55.92M 10-K · filed 2024-02-28 | $55.92M 10-Q · filed 2021-08-11 |
| 2020-09-30 | $59.68M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $75.78M 10-Q · filed 2021-08-11 | |
| 2019-12-31 | $26.75M 10-K · filed 2022-03-24 | |
| 2018-12-31 | $26.75M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $46.37M 10-Q · filed 2018-11-09 | |
| 2017-12-31 | $48.61M 10-K · filed 2020-03-13 | |
| 2016-12-31 | $9.91M 10-K · filed 2019-03-13 | |
| 2015-12-31 | $10.44M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |